APO-ACYCLOVIR TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

ACYCLOVIR

Sẵn có từ:

APOTEX INC

Mã ATC:

J05AB01

INN (Tên quốc tế):

ACYCLOVIR

Liều dùng:

200MG

Dạng dược phẩm:

TABLET

Thành phần:

ACYCLOVIR 200MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

100/500

Loại thuốc theo toa:

Prescription

Khu trị liệu:

NUCLEOSIDES AND NUCLEOTIDES

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0115506002; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

1997-08-21

Đặc tính sản phẩm

_____________________________________________________________________________________
_APO-ACYCLOVIR Product Monograph _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
APO-ACYCLOVIR
ACYCLOVIR TABLETS
APOTEX STANDARD
200 MG, 400 MG AND 800 MG
ANTIVIRAL AGENT
APOTEX INC. DATE OF PREPARATION:
150 SIGNET DRIVE
April 10, 1997
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
August 31, 2021
Control No. 255331
_____________________________________________________________________________________
_APO-ACYCLOVIR Tablets Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..............................................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................................
6
DRUG INTERACTIONS
..........................................................................................................................................
9
DOSAGE AND ADMINISTRATION
......................................................................................................................
9
OVERDOSAGE
......................................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................................